

# Zantac

RANITIDINE HC/

## Keeping you in control

**PRESCRIBING INFORMATION:** **Indications** Duodenal ulcer, benign gastric ulcer, ulcers associated with non-steroidal anti-inflammatory drugs (NSAIDs), prevention of NSAID-associated duodenal ulcer, oesophageal reflux disease, severe oesophagitis, chronic episodic dyspepsia. **Dosage Adults:** Duodenal ulceration and gastric ulceration: A single 300mg dose at bedtime or 150mg twice daily in the morning and evening for four weeks. Alternatively, in duodenal ulcers, 300mg in the morning and evening for four weeks to achieve optimal healing. Continued maintenance treatment of 150mg at bedtime is recommended for patients with a history of recurrent ulceration. Ulcers following non-steroidal anti-inflammatory drug therapy or associated with continued non-steroidal anti-inflammatory drugs: 150mg twice daily for up to eight weeks. Prevention of NSAID-associated duodenal ulcer: 150mg twice daily concomitantly with NSAID therapy. Chronic episodic dyspepsia: 150mg twice daily for six weeks, investigate early relapsers and non-responders. Oesophageal reflux disease: 300mg at bedtime or 150mg twice daily for up to eight weeks. Moderate to severe oesophagitis: 150mg four times daily for up to twelve weeks (see data sheet for full dosage instructions). **Children:** Oral dose for peptic ulcer: 2mg/kg to 4mg/kg, twice daily to a maximum of 300mg per day. **Contra-indications** Patients with known hypersensitivity to ranitidine. **Precautions** In patients in whom sodium restriction is indicated, care should be taken when administering sodium-containing Effervescent Tablets. Exclude the possibility of malignancy in gastric ulcer before instituting therapy, especially in middle-aged patients with new or recently changed dyspeptic symptoms. Regular supervision of patients taking NSAIDs concomitantly with Zantac is recommended, especially if elderly. Reduce dosage in the presence of severe renal failure (see data sheet). Avoid in patients with history of porphyria. Effervescent Tablets contain aspartame, use with caution in patients with phenylketonuria. Like other drugs, use during pregnancy and lactation only if strictly necessary. **Side effects** Headache, dizziness, skin rash, occasional hepatitis, rarely arthralgia, myalgia. Rarely, reversible mental confusion states, usually in very ill or elderly patients. Rare cases of leucopenia and thrombocytopenia, usually reversible, agranulocytosis and pancytopenia. Hypersensitivity reactions, anaphylactic shock. Rare cases of breast symptoms in men. As with other  $H_2$ -receptor antagonists rare cases of bradycardia, A-V block and asystole (see data sheet). **Presentations** Zantac 150 Tablets each containing 150mg ranitidine HC/ (Product licence number 0004/0279, 60 tablets £29.76); Zantac 300 Tablets each containing 300mg ranitidine HC/ (Product licence number 0004/0310, 300ml bottle £22.32). **Product licence holder** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE.

# Glaxo

Effervescent Tablets each containing 150mg ranitidine HC/ and 14.3mEq sodium (Product licence number 0004/0392, 60 tablets £31.25); Zantac Effervescent Tablets each containing 300mg ranitidine HC/ and 20.8mEq sodium (Product licence number 0004/0393, 30 tablets £31.25); Zantac Syrup each 10ml dose containing 150mg ranitidine HC/ (Product licence number 0004/0310, 300ml bottle £22.32). **Product licence holder** Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. **(POM)** Zantac is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex, UB11 1BT. Telephone: 081-990 9444. February 1993.

**PRESCRIBING INFORMATION** **Properties:** Prepulsid is the first of a new class of drug capable of correcting abnormal motility throughout the GI tract. **Indications:** GASTRO-OESOPHAGEAL REFLEX DISEASE: Treatment of the symptoms such as heartburn, regurgitation and healing of mucosal lesions. Prepulsid may also be used for the maintenance treatment of reflux oesophagitis. **DYSPEPSIA:** Treatment of symptoms such as epigastric pain, early satiety, bloating, where organic disease has been excluded. **IMPAIRED GASTRIC EMPTYING:** Relief of the symptoms such as epigastric pain, early satiety, anorexia, bloating and nausea associated with delayed gastric emptying secondary to systemic sclerosis and autonomic neuropathy of diabetes. **Dosage and Administration:** ADULTS AND CHILDREN TWELVE YEARS AND OVER: Take 15 minutes before food. **Gastro-oesophageal reflux:** 10mg Prepulsid tds. Night time symptoms can be treated with an extra 10mg dose at bedtime. A 12 week course is recommended for healing oesophagitis. Patients may continue long term maintenance therapy at a dose of 20mg once daily (at bedtime) or alternatively, 10mg twice daily (before breakfast and at bedtime). In patients whose lesions were initially very severe, this dose can be increased to 20mg twice daily. **Dyspepsia:** 10mg Prepulsid tds. The usual course of treatment is 4 weeks. **Impaired gastric emptying:** 10mg Prepulsid tds or qds. An initial course of 6 weeks is recommended but longer treatment may be required. **Use in children:** Not

recommended in children under 12. **Use in elderly:** Dose as for adults, but monitor response. **Abnormal renal or liver function:** Initially the dose should be halved. **Contra-indications, warnings etc.** **Contra-indications:** Contra-indicated in pregnancy and in patients in whom gastrointestinal stimulation might be dangerous, e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation. **Warnings:** It is not advisable to take Prepulsid whilst breastfeeding. **Drug Interactions:** The absorption from the stomach of concomitantly administered drugs may be diminished, whereas absorption of drugs from small intestine may be accelerated. For drugs that require careful individual titration, such as anticonvulsants, it may be useful to measure their plasma concentration. In patients receiving anticoagulants, the prothrombin time may be increased. Prepulsid does not affect psychomotor performance nor does it induce sedation or drowsiness. However, the sedative effects of benzodiazepines and alcohol may be accelerated when administered concomitantly with Prepulsid. The effects of Prepulsid are antagonized by anticholinergic drugs. **Side-effects:** Abdominal cramps, borborygmi and loose stools (diarrhoea) are mainly transient and rarely require discontinuation of treatment. Should severe abdominal cramps occur with single administrations of 20mg Prepulsid, it is recommended that the dose is halved. Infrequent side-effects include headache and lightheadedness. Reports of convulsions and extrapyramidal effects have been received.

Exceptionally, reversible liver function abnormalities have been reported - causal relationship not established. **Overdosage:** Treatment should include activated charcoal, close observation and general supportive measures. **Presentation and packaging:** Prepulsid Tablets; white, biconvex, scored tablets, engraved C15/10 on one side and Janssen on the reverse in packs of 120. Each tablet contains 10mg of cisapride. The tablets also contain lactose. Prepulsid Suspension; white, cherry-flavoured suspension containing cisapride 1mg/ml, 500ml bottle. The suspension also contains sucrose, methyl and propyl parabens. **Pharmaceutical Precautions:** Prepulsid Tablets; store at room temperature in a dry place and protect from light. Prepulsid Suspension; store at room temperature (below 25°C). **Product Licence Numbers:** Prepulsid 10mg tablets PL 0242/0136. Prepulsid suspension 500ml PL 0242/0157. **Basic NHS Cost:** 120 tablets - £38.57; 500ml bottle suspension - £16.00. **Legal Category:** POM. **Date of last revision:** November 1992. (Correct at time of printing). **Reference:** 1. Blum AL et al. 1991. (Data on file.)

Further information is available from  
 **JANSSEN**  
 PHARMACEUTICAL LTD  
 Grove, Wantage, Oxon, OX12 0DQ  
 TM=Trademark © JPL/268/92

**NOW  
APPROVED  
FOR MAINTENANCE**

# THE SQUEEZE THAT RELIEVES



## WHEN ANTACIDS HAVE FAILED

New maintenance Prepulsid, taken once daily at night, effectively reduces recurrence of reflux oesophagitis symptoms, significantly delays relapse, and provides long term relief.<sup>1</sup>

# PREPULSID<sup>TM</sup>

**ONCE DAILY  
NEW IN  
MAINTENANCE  
20mg NOCTE**

cisapride

**PROMOTES AND MAINTAINS GASTRO-OESOPHAGEAL MOTILITY**

#### **Losec Capsules Abbreviated Prescribing Information**

**Presentation:** Losec Capsules containing 20mg omeprazole. **Uses:** Treatment of reflux oesophagitis. Symptom relief is rapid, and the majority of patients are healed after 4 weeks. Treatment of duodenal and gastric ulcers, including those complicating NSAID therapy. Zollinger-Ellison syndrome. **Dosage & administration:** *Adults (including elderly):* Reflux oesophagitis: 20mg once daily, given for 4 weeks. For those patients not fully healed after the initial course, healing usually occurs during a further 4-8 weeks treatment. Losec has also been used in a dose of 40mg once daily in patients with reflux oesophagitis refractory to other therapy. Healing usually occurred within 8 weeks. Patients can be continued at a dosage of 20mg once daily. *Duodenal and benign gastric ulcers:* 20mg once daily. The majority of patients with duodenal ulcer are healed after 4 weeks. The majority of patients with benign gastric ulcer are healed after 8 weeks. In severe cases, the dose may be increased to 40mg Losec once daily. Long-term therapy with Losec in the treatment of gastric and duodenal ulcers is not currently recommended. *Zollinger-Ellison syndrome:* 60mg once daily. The dosage should be adjusted individually and treatment continued as long as clinically indicated. More than 90% of patients with severe disease and inadequate response to other therapies have been effectively controlled on doses of 20 - 120mg daily. With doses above 80mg, give twice daily. *Children:* There is no experience of the use of Losec in children. *Impaired renal or hepatic function:* Adjustment is not required. Patients with severe liver disease should not require more than 20mg Losec daily. **Contra-indications, warnings:** No known contra-indications to the use of Losec. When gastric ulcer is suspected, the possibility of malignancy should be excluded before treatment with Losec is instituted, as treatment may alleviate symptoms and delay diagnosis. Avoid in pregnancy unless there is no safer alternative. Breast feeding should be discontinued if the use of Losec is considered essential. Losec is well tolerated. All the following adverse reactions have usually been mild and transient, and there has been no consistent relationship with treatment: Nausea, headache, diarrhoea, constipation, flatulence, skin rashes, urticaria, pruritus, dizziness, somnolence, insomnia, vertigo, malaise, paraesthesia have occurred rarely. In isolated cases the following have been reported: muscular weakness, arthralgia, myalgia, blurred vision, dysgeusia, peripheral oedema, gynecomastia, leucopenia, thrombocytopenia, GI candidiasis and stomatitis. Reversible mental confusion, agitation, depression and hallucinations have occurred predominantly in severely ill patients. Increases in liver enzymes with or without increases in bilirubin values have been observed. Losec can delay the elimination of diazepam, phenytoin and warfarin. Monitoring of patients receiving warfarin or phenytoin is recommended and a reduction of warfarin or phenytoin dose may be necessary when omeprazole is added to treatment. No evidence of an interaction with theophylline, propranolol, metoprolol, lidocaine, quinidine, amoxycillin or antacids. The absorption of Losec is not affected by alcohol or food. **Animal Toxicology:** Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole or subjected to partial fundectomy. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition, and not from a direct effect of any individual drug. No treatment related mucosal changes have been observed in patients treated continuously with omeprazole for periods up to 5 years. **Pharmaceutical precautions:** Use within three months of opening. Replace cap firmly after use. Dispense in original container. **Legal category:** POM **Package quantities:** Bottles of 5 capsules, £6.49; Bottles of 28 capsules, £36.36 **Product licence no:** PL0017/0238 **Product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.

#### **References**

1. Holt S & Howden CW. Dig Dis & Sci 1991; 36 (4): 385-93.
2. Sandmark S et al. Scand J Gastroenterol 1988; 23: 625-32.
3. McFarland RJ et al. Gastroenterol 1990; 98: 278-83.
4. Bate CM et al. Gut 1990; 31: 968-72.

# **ASTRA**

For further information contact the product licence holder:  
Astra Pharmaceuticals Ltd., Home Park, Kings Langley,  
Herts WD4 8DH. Telephone: (0923) 266191.

\*Losec compared with conventional starting courses of H<sub>2</sub>-antagonists in reflux oesophagitis, duodenal and gastric ulcers.

LOSEC is a registered trademark

Date of Preparation: January 1993





# SETS THE STANDARD

FROM THE START  
IN REFLUX OESOPHAGITIS,  
DUODENAL AND GASTRIC ULCERS

*One 20mg capsule daily*

 **LOSEC**®  
omeprazole-Astra

*Rapid relief Accelerated healing\*<sup>1-4</sup>*

# THE QUALITIES OF LEADERSHIP



## Experience

Unique among foam treatments, Colifoam has over 12 years of proven efficacy and safety in clinical practice.

## Trust

Equally as effective as steroid enemas,<sup>1,2</sup> Colifoam is well documented and is

the most prescribed topical treatment<sup>3</sup> for ulcerative colitis.

## Confidence

Colifoam's simplicity and effectiveness has transformed the lives of thousands of patients, enabling them to pursue active social and working lives.<sup>1</sup>

**COLIFOAM**  
10% Hydrocortisone acetate foam.

## The leading topical treatment for ulcerative colitis.

**PRESCRIBING INFORMATION:** Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. References 1. Somerville KW et al. British Medical Journal 1985; 291:866. 2. Ruddell WSJ et al. Gut 1980; 21:885-889. 3. Independent Research Audit. Data on File. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Broadwater Road, Welwyn Garden City, Herts. AL7 3SP.



# Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.


**colofac**<sup>®</sup>   
mebeverine  
loosens the grip of IBS

**Presentation.** 1. White round sugar-coated tablets with no superficial markings each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. 2. Yellow banana flavoured sugar free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml. Basic NHS price £3.50. **Indications** 1. Irritable Bowel Syndrome. 2. Gastro-intestinal spasm secondary to organic diseases. **Dosage and Administration.** Tablets: Adults (including the elderly) and children ten years and over: one tablet three times a day, preferably 20 minutes before meals. Suspension: Adults (including the elderly) and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-Indications, Warnings, etc.** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** Tablets: 0512/0044. Suspension: 0512/0061. **Legal Category:** POM. ® Registered Trade Mark. Further information is available from: Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Tel: 0703 472281. Date of last review January 1993.

**duphar**

A member of the Solvay Group.


COL/HOSP/JA/JAN 93




LESS HEADACHE THAN  
SULPHASALAZINE<sup>2</sup>



NO SULPHAPYRIDINE-INDUCED  
INFERTILITY<sup>3</sup>



LESS GASTROINTESTINAL UPSET  
THAN SULPHASALAZINE<sup>2</sup>



LESS HAEMATOLOGICAL COMPLICATIONS  
THAN SULPHASALAZINE<sup>2</sup>

**Prescribing Information:** **Presentation:** 'Asacol' Tablets, PL 0002/0173, each containing 400 mg mesalazine (5-aminosalicylic acid) coated with a pH-dependent acrylic based resin (Eudragit S) formulated to release the active ingredient in the terminal ileum and colon. Blister packs of 120 (12 × 10), £34.30. 'Asacol' Suppositories 250 mg, PL 0002/0158, each containing 250 mg mesalazine, 20, £6.50. 'Asacol' Suppositories 500 mg, PL 0002/0195, each containing 500 mg mesalazine, 10, £6.50. **Uses:** Treatment of mild to moderate acute exacerbations of ulcerative colitis. Maintenance of remission of ulcerative colitis. Suppositories particularly appropriate for

distal disease. **Dosage and administration:** **Tablets:** *Adults:* *Acute disease:* 6 tablets a day, in divided doses, with concomitant corticosteroid therapy where clinically indicated. *Maintenance therapy:* 3 to 6 tablets a day, in divided doses. *Children:* No dosage recommendation. **Suppositories:** *Adults:* 250 mg strength: 3 to 6 a day, in divided doses, with the last dose at bedtime. 500 mg strength: A maximum of 3 a day, in divided doses, with the last dose at bedtime. *Children:* No dosage recommendation. **Contraindications:** A history of sensitivity to salicylates. Severe renal impairment (GFR <20 ml/min). Children under 2 years of age. **Precautions:** Best

# WHY THE MAJORITY OF SPECIALISTS USE 'ASACOL' FIRST

A survey of 50 BSG consultant members found that 60% of them would select 'Asacol' Tablets as their first-line maintenance therapy for ulcerative colitis, on the basis of tolerance, efficacy and previous experience.<sup>1</sup>

'Asacol' Tablets are equally as effective as sulphasalazine in maintenance treatment but are significantly better tolerated, and can avoid the side effects associated with sulphapyridine.<sup>2</sup> Because of their superior tolerability, 'Asacol' Tablets can be used in higher doses to gain stabilisation of active disease,<sup>4,5</sup> and have been shown to provide greater symptomatic relief than sulphasalazine.<sup>4</sup>

When patients have been transferred to 'Asacol' Tablets the majority of them have said they prefer them to their previous therapy and would be happy to take 'Asacol' again.<sup>6</sup>

Four very good reasons to use 'Asacol' first.

**ASACOL**  
mesalazine\*  
(5-aminosalicylic acid) **400mg**

## COLITIS CONTROL WITHOUT SULPHAPYRIDINE

avoided in patients with established renal impairment but, if necessary, use with caution. Avoid during pregnancy and lactation. Caution in elderly and only where renal function is normal. Do not give tablets with lactulose or similar preparations which lower stool pH. Adverse reactions: Nausea, diarrhoea, abdominal pain, headache. Exacerbation of symptoms of colitis. Reports of leucopenia, neutropenia, thrombocytopenia, pancreatitis, hepatitis, interstitial nephritis, nephrotic syndrome, renal failure with oral treatment usually reversible. Suspect nephrotoxicity in patients developing renal failure. Legal category: POM. 24.4.91.

### References

1. Cole AT *et al.* Gut 1990;31:A1205. 2. Riley SA *et al.* Gastroenterology 1988;94:1383-9. 3. Riley SA *et al.* Gut 1987;28:1008-12. 4. Riley SA *et al.* Gut 1988;29:669-674. 5. Sninsky CA *et al.* Ann Intern Med 1991; 115:350-5. 6. Pera A *et al.* Ital J Gastroenterol 1991;23(9):647.  
Smith Kline & French Laboratories, Welwyn Garden City, Hertfordshire AL7 1EY. © 1993 Smith Kline & French Laboratories. Authorised user of the trade mark 'Asacol' in the UK. \*Mesalazine is the British approved name of 5-aminosalicylic acid.

**SK&F**  
0193AS:AD/2/116



# SCANDINAVIAN JOURNAL OF *Gastroenterology*

## One of the leading and most cited journals within gastroenterology

Presents international communications of original research in all spheres of gastroenterology and from all major research centers worldwide. Ensures rapid publication of articles in both clinical and experimental gastroenterology corresponding to the high quality standards of the journal. Publication time is currently 4 - 6 months. Indexed in, among others, Current Contents, Excerpta Medica and Index Medicus.

Published in English, Spanish, and Chinese. Total circulation: 26,000. The English edition contains 1140 pages per volume (12 issues), and supplements are sent free of charge to the subscribers.

## A selection of articles for 1993

Reduced Sensitivity to Intra-Oesophageal Acid in Patients with Reflux-Induced Strictures. *P.J. Winwood, C.C. Mavrogiannis & C.L. Smith.*

Nitric Oxide Release in Response to Gut Injury. *M.J.S. Miller, X.J. Zhang, H. Sadowska-Krowicka, S. Chotinaruemol, J.A. McIntyre, D.A. Clark & S.A. Bustamante.*

Specificities of Monoclonal Antibodies to Domain I of  $\alpha$ -Gliadins. *H.J. Ellis, A.P. Doyle, H. Wieser, R.P. Sturgess & P.J. Ciclitira.*

Height, Weight, and Risk of Colorectal Cancer. An 18-Year Follow-up in a Cohort of 5249 Men. *P. Suadicani, H.O. Hein & F. Gyntelberg.*

Gastric Mucosal Microcirculation and Purine Nucleotide Metabolism after Retransfusion of Rats in Hemorrhagic Shock. *T. Ekman, B. Risberg, B. Soussi & U. Bagge.*

Different Modes of Fragmentation of Gallstones in Extracorporeal Shockwave Lithotripsy. *R. Nitsche, V. Schweinsberg, H. Klengel, P.D. Niedmann & U.R. Fölsch.*



Send to: Scandinavian University Press, Journals Customer Services, P.O. Box 2959 Tøyen, N-0608 Oslo, Norway.  
U.S. Address: Scandinavian University Press, 200 Meacham ave., Elmont, NY 11003, U.S.A.

☐ Please enter my/our subscription to SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, ISSN 0036-5521, starting with no. 1/93. Subscription rate 1993: Norwegian Kroner 2500,- (Approx. USD 465.00).

*Issued monthly. Postage included. Airspeed delivery worldwide. Prepayment required.*

☐ Please send me a free sample copy of SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY.

### Please tick one box:

☐ Cheque enclosed ☐ Send invoice ☐ VISA ☐ Eurocard/Mastercard ☐ Am.Ex. ☐ Diners

Card No.:                 Exp. date: \_\_\_\_\_

*Please make the cheque payable to Scandinavian University Press and staple it to your order form.*

Signature: \_\_\_\_\_

Name [PLEASE USE BLOCK LETTERS]: \_\_\_\_\_

Address: \_\_\_\_\_

\_\_\_\_\_

# Why settle for 54% remission when you can achieve 76%?<sup>1</sup>



Ulcerative colitis can ruin lives with its distressing cycle of relapses. Surely the most rewarding strategy, once you've done the job of controlling the acute phase of this disease, is to maintain remission as effectively as possible.

A recent clinical study indicated a comfortable advantage for Dipentum over coated mesalazine in the maintenance of remission in ulcerative colitis.<sup>2</sup> The findings of this study have been incorporated into a paper published in *The Lancet*<sup>1</sup>, giving Dipentum 22% superiority in 12-month remission rates. But then what would you expect from a 5-ASA treatment that can deliver 99% of an oral dose to the colon?

IN ULCERATIVE COLITIS

 **Dipentum**<sup>®</sup>  
olsalazine sodium

Because remission means so much

**PRESCRIBING INFORMATION:** **Dipentum** **Presentation:** Caramel coloured capsules containing 250mg olsalazine sodium. **Uses:** Oral treatment of acute mild ulcerative colitis and the maintenance of remission. Olsalazine consists of two molecules of 5-amino-salicylic acid (5-ASA) joined through an azo-bond. The systemic absorption of olsalazine is minimal: 99% of an oral dose will reach the colon. Olsalazine is activated in the colon where it is converted into 5-ASA. The release of 5-ASA is neither pH nor time dependent. 5-ASA acts topically on the colonic mucosa and local colonic concentrations of 5-ASA are more than 1000 times that found in the serum. **Dosage and Administration:** **Acute Mild Disease:** Adults including the Elderly: Commence on 1g daily in divided doses and, depending upon the patient response, titrate the dose upwards to a maximum of 3g daily over 1 week. A single dose should not exceed 1g. Olsalazine should be taken with food. **Remission:** Adults including the Elderly: Two capsules (0.5g) twice daily taken with food. **Contra-indications:** Hypersensitivity to salicylates. There is no experience of the use of olsalazine in patients with significant renal impairment. Olsalazine is contra-indicated in patients with significant renal impairment. **Pregnancy:** Reproduction studies performed in mice, rats and rabbits have revealed no evidence of impaired fertility, harm to the foetus or teratogenic effects due to olsalazine administration. However, the experience of use in pregnant women is limited. Dipentum should not be used during pregnancy unless the clinician considers that the potential benefit outweighs the possible risk to the foetus. **Lactation:** There are no data on the excretion of olsalazine in breast milk. **Adverse Reactions:** Watery diarrhoea has been recorded in 15% of patients treated. In half of these patients the diarrhoea was either transient or overcome by dose reduction. In patients who do not respond to dose reduction the drug should be stopped. As with sulphasalazine and mesalazine gastrointestinal side-effects are the most common. The most frequently reported adverse reactions are diarrhoea, abdominal cramps, headache, nausea, dyspepsia, arthralgia and rash. **Treatment of Overdose:** There is no specific antidote to olsalazine. Treatment should be supportive. **Pharmaceutical Precautions:** Store at room temperature in a dry place. **Legal Category:** POM. **Package Quantities:** Containers of 100 capsules. **NHS Price:** 100 capsules £23.90. **Further Information:** Olsalazine has been used concomitantly with glucocorticosteroids. **Product Licence Number:** 0009 0069. **Product Licence Holder:** Pharmacia Biosystems Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **Distributed by:** Kabi Pharmacia Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **References:** 1. Courtney M.G. et al. (1992) *The Lancet*, 339: 1279-1281. 2. Courtney M.G. et al. (1990) *The 9th World Congress of Gastroenterology*, Sydney, Australia. Abstr. PP727. KV1421/3/93

 **Kabi Pharmacia**


# THE UNACCEPTABLE FACE OF SCIENCE

Fraud exists, both in academic medical research and in drug trials in general practice. This important new book sets out the evidence, reviewing events since 1975 when the first notorious case of fraud became public knowledge.

The problem is viewed from many perspectives, with contributions from a general practitioner, head of an academic unit, contract research company director, statistician, editor and lawyer. Together, their information provides a compelling account of the extent to which fraud and misconduct have been and continue to be practised in medicine.

## Contents include:

- Fraud in general practice
- Statistical aspects of detection
- The British Pharmaceutical Industry's response
- Legal aspects
- The French scene
- The Danish scene
- Data audits in trials and their implications for misconduct (USA)
- Fraud and the editor



**Fraud and Misconduct in Medical Research** is a valuable practical text for all researchers – and ultimately anyone who practises medicine.

*Publication date:* January 1993

*Price:* UK £24.95; Overseas £27.00 (including postage by air abroad)

*BMA Members Price:* UK £22.95; Overseas £25.00 (including postage by air abroad)

*ISBN:* 0-7279-0757-3

## Also available


### **A Difficult Balance: Editorial Peer Review in Medicine**

Third Impression (1991)

*Price:* UK £12.95; Overseas £15.50 (including postage by air abroad)

*BMA Members Price:* UK £11.95; Overseas £14.50 (including postage by air abroad)

*ISBN:* 0-7279-0310-1



## ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE**

Please send me the following books:

Qty	Title	Amount

Prices include postage by air abroad ☐ Please send me a book catalogue

Total £

Name  
(Print clearly)

Address

Postcode

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_ Membership No \_\_\_\_\_



Debit my AMERICAN EXPRESS / VISA / MASTERCARD Card No \_\_\_\_\_

Expiry date \_\_\_\_\_ Signature \_\_\_\_\_

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

**BMJ**  
PUBLISHING GROUP

# A NEW FORCE IN PANCREATIC EXOCRINE INSUFFICIENCY



*New*  
**creon<sup>®</sup>**  
pancreatin  
**25000**

Superior control of steatorrhoea<sup>†</sup>

<sup>†</sup> Compared with standard enteric-coated tablets in pancreatic insufficiency<sup>1,2</sup>

#### Prescribing Information

**Presentation:** Opaque orange/yellow hard gelatin capsules containing brownish coloured enteric coated pellets of pancreatin, equivalent to:

25,000 BP units of lipase  
18,000 BP units of amylase  
467 BP units of protease

Available in packs of 50. Basic NHS price £19.50

**Indication:** Pancreatic exocrine insufficiency.

**Dosage and Administration:** Adults (including elderly) and children: Initially one capsule with meals, then adjust according to response.

The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

**Contra-indications, Warnings, etc.** Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of

porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of pancreatin.

Overdosage although not experienced until now, could precipitate meconium ileus equivalent. Perianal irritation, and rarely, inflammation, could occur when large doses are used.

**Product Licence Number:** 5727/0006

**Name and Address of Licence Holder**

Kali Chemie Pharma GmbH, Hans-Böckler-Allee 20, 3000, Hannover 1, Germany.

#### References

1. Stead R J et al. *Thorax* 1987; **42**: 533-37
2. Beverley D W et al. *Arch Dis Child* 1987; **62**: 564-68

Further information is available from:

Duphar Laboratories Limited, Gaters Hill, West End,

Southampton SO3 3JD. Tel: (0703) 472281.

© Registered Trade Mark

CRE/CP/JA/AUG 92

**duphar**  
A member of  
the Solvay Group.